Stock Forecast

  Nicox S.A. ( COX.PA) Stock. Should you Buy or Sell?    $ 1.90

0.06 (3.17 %)



Nicox S.A. Analysis

Updated on 08-08-2022
Symbol COX.PA
Price $1.90
Beta 1.427
Volume Avg. $38.03 thousand
Market Cap $82.13 M
52 Week Range $1.594 - $3.84


Nicox S.A. opened the day at $1.90 which is +'3.17 % on yesterday's close. Nicox S.A. has a 52 week high of $3.84 and 52 week low of $1.594, which is a difference of $2.246. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $82.13 M and total net profit is $8583000 which means the company is trading at 9.57 times profit to market capitalization. Theoretically, if you were to buy Nicox S.A. for $82.13 M, it would take 15 years to get your money back. Nicox S.A. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Nicox S.A. Stock Forecast - Is Nicox S.A. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio -1.554
Dividend Yiel 0.000
Net Profit Margin -23.819


Valuing Nicox S.A.


Price Book Value Ratio 0.366 Price To Book Ratio 0.366
Price To Sales Ratio 37.004 Price Earnings Ratio -1.554


How liquid is Nicox S.A.


Current Ratio 5.967
Quick Ratio 5.246


Debt


Debt Ratio 0.341 Debt Equity Ratio 0.517
Long Term Debt To Capitalization 0.219 Total Debt To Capitalization 0.222



Latest news about Nicox S.A.






About Nicox S.A.


CEO : Mr. Michele Garufi
Sector : Healthcare
Industry : Biotechnology

Website : https://www.nicox.com

Exchange : Paris

Description :

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.


My Newsletter

Sign Up For Updates & Newsletters